Skip to main content
SPARC - Logo
Innovations Inspired by life
Menu

Hamburger

  • Our Company
    • Who we are
    • History
    • Culture
    • Board of Directors
    • Leadership Team
  • OUR RESEARCH
    • Therapeutic focus
    • Delivery Technologies
    • Research Programs
    • R&D Pipeline
  • Our Medicines
    • Xelpros®
    • Elepsia® XR
  • Business Development
    • Strategy
    • Partner with us
  • Accreditations And Approvals
    • Good Laboratory Practice
  • Investors
    • Who we are
    • Financials
    • Annual reports
    • Presentations
    • Chairman's Speech
    • Committees of BOD's
    • Shareholding pattern
    • Announcements & Disclosures
    • Policies & Codes
    • Listing Information
    • Board of Directors
    • FAQ’s, Guide Book and Forms for Shareholders
    • Investors Contact
    • Go green
    • IEPF
  • Media
    • Press Releases
    • Presentations
  • Careers
    • Overview
    • Apply Now
  • Contact Us
Our Research » Research Programs
  • Research Programs
    • Phenobarbital Injection
    • SCO - 088
    • SCD - 044
    • SCC - 138
    • SCO - 120

SCO - 120

SCO-120 is a novel, orally-active, Selective Estrogen Receptor Degrader (SERD) targeting both wild type and mutant forms of ER.

Anti-estrogen therapy is the mainstay of treatment for women with breast cancer whose tumors express ERα and the degradation of ERα is deemed a superior therapeutic approach in the treatment of ER +ve breast cancer.

Also, it is known that approximately 20-50% of patients with metastatic breast cancer develop resistance to antiestrogen therapies due to the emergence of mutations in the ERα. Given the current treatment options, there is an unmet need for an orally bioavailable SERD that can target both wild type and mutant forms of ER.

SCO-120 has demonstrated potent in-vitro SERD activity in breast cancer cells expressing ERα wild type (WT) and its mutants. Along with this it has also shown robust tumor growth inhibition of Wild Type (WT) as well as Y537S and D538G xenografts.

Furthermore, SCO-120 has been studied in combination with a CDK 4/6 inhibitor and the effects have shown to be further enhanced in these pre-clinical combination studies.
 

Sco - 120

SPARC has initiated a Phase 1 study in the US to assess the PK and Safety of SCO-120 in healthy volunteers.

Our Company

  • Who we are
  • history
  • Culture
  • board of directors
  • Leadership team

Our Research

  • Therapeutic focus
  • Delivery Technologies
  • Research Programs
  • R&D Pipeline

Investor Relations

  • Financials
  • Announcements & Disclosures
  • Shareholding pattern
  • Listing Information

Quick Links

Quick Links

  • Business Development
  • Investors
  • Media
  • Careers

Social Connect

  • twitter
  • linkedin

Employee Portal »

Copyright © 2019. Sun Pharma Advanced Research Company Ltd. All rights reserved.
Terms of Use  |   Archival Policy   |   Sitemap
Site Credits